Switzerland· 65564002
Tenofovir-Mepha, Filmtabletten
A tenofovir disoproxil product containing tenofovirum, registered in Switzerland by Mepha Pharma AG and dispensed under Swissmedic category A. The same ATC class is registered in 15 of our 19 countries.
Checked against Swissmedic (Switzerland) on
Informational only — not a medical device.
Where it is registered
Tenofovir disoproxil is registered in 15 of 19 countries.
Countries holding a registration under ATC J05AF07 (tenofovir disoproxil), each read from that country’s own register.
- This record: Switzerland, from Swissmedic (Switzerland)
- 9 of them publish a price we can compare per daily dose
Tenofovir disoproxil · ATC J05AF07
15 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of tenofovir disoproxil costs, country by country.
Normalised to the WHO defined daily dose (0.245 g), the median price runs from $0.24 in United States to $14.17 in Switzerland — a ×59 gap.
- Switzerland: $14.17 per daily dose (median across products in the class)
- Public list prices, converted to USD at the rate date shown
- US figures are pharmacy acquisition cost (CMS NADAC), not retail
Tenofovir disoproxil · price per daily dose (0.245 g)
USD · FX 28 Sept 2026
- CH Switzerland$14.17
- FR France$4.15
- US United States$0.24 (acquisition cost)
The record
At a glance
Swissmedic (Switzerland)- Active substance
- tenofovirum
- Manufacturer
- Mepha Pharma AG
- Country
- Switzerland (CH)
- ATC code
- J05AF07
- ATC class
- Tenofovir disoproxil
- Defined daily dose
- 0.245 g, O
- Swissmedic category
- A
- Reimbursed
- No
- Source register
- Swissmedic (Switzerland)
- Last checked
- September 12, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
4 interactions on record for tenofovir disoproxil.
Mechanism, severity and management for each pair, from a commercially licensed source — included with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Tenofovir disoproxil · interactions on record
4 records
4 more interactions with mechanism and management, from a commercially licensed source.
Sign in to checkSame class
Other records under J05AF07
Tenofovir disoproxil, as other registers publish it.
- CanadaAG-TENOFOVIRANGITA PHARMA INC.
- CanadaAPO-TENOFOVIRAPOTEX INC
- CanadaAURO-TENOFOVIRAURO PHARMA INC
- FinlandIctadySanoSwiss UAB
- CanadaJAMP-TENOFOVIRJAMP PHARMA CORPORATION
- CanadaMINT-TENOFOVIRMINT PHARMACEUTICALS INC
- CanadaMYLAN-TENOFOVIR DISOPROXILMYLAN PHARMACEUTICALS ULC
- CanadaNAT-TENOFOVIRNATCO PHARMA (CANADA) INC
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/ab647f5a-17cd-4ff1-967f-a1294ff95e6f GET /v1/drugs/ab647f5a-17cd-4ff1-967f-a1294ff95e6f?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{}See everything about tenofovir disoproxil.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.